Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first ...
NORTH CHICAGO, Ill., Dec. 2, 2025 /PRNewswire/ -- AbbVie today announced it will unveil new data at the 2025 American Society of Hematology (ASH) Congress, showcasing continued advances in research ...
A version of this story appeared in Volume 103, Issue 11 Chemists and chemical biologists just keep dreaming up new ways to interfere with biomolecules. That research frequently leads to promising ...
Additional oral presentations explore odronextamab in areas of high unmet need, including the primary analysis in diffuse large B-cell lymphoma progressing after CAR-T therapy and first results in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results